<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095053</url>
  </required_header>
  <id_info>
    <org_study_id>euploid versus morphology</org_study_id>
    <secondary_id>Optimizing implantation in FET</secondary_id>
    <nct_id>NCT03095053</nct_id>
  </id_info>
  <brief_title>PGT-A Versus Blastocyst Morphology Selection</brief_title>
  <official_title>PGT for Aneuploidy Does Not Enhance Live Birth in Young Patients (≤35 Years): a Randomized Controlled Trial of Single Blastocyst Frozen Embryo Transfers (ClinicalTrials.Gov ID: NCT03095053)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antalya IVF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antalya IVF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction Embryo aneuploidy is likely the leading cause of implantation failure in IVF
      cycles. Since the inception of IVF, non-invasive morphology based scoring has been the most
      widely used embryo selection method, resulting in relatively low embryo implantation rates.
      Our understanding of the optimal conditions required for in vitro embryo culture in IVF has
      advanced significantly over the past two decades. The implementation of improved in vitro
      embryo culture technologies (i.e., culture media and incubators) has resulted in an increase
      in the number of good quality embryos and consequently in increased numbers of blastocysts.
      While blastocyst transfers have seemingly improved the reproductive outcomes of IVF, they
      still remain suboptimal. The main objective of this randomized controlled trial (RCT) will be
      to investigate whether preimplantation genetic testing (i.e., PGT with comprehensive
      chromosome screening (CCS)) for aneuploidy is a superior embryo selection method, with the
      live birth outcomes of euploid blastocyst frozen embryo transfers (FET) compared with the LB
      outcomes of unknown-ploidy blastocyst FET, with blastocysts selected on (standard)
      morphological score.

      Methods This RCT will be conducted at a single private IVF centre performing routine
      segmented-IVF, with intracytoplasmic sperm injection (ICSI), blastocyst freeze-all, and
      artificial frozen embryo transfer (art-FET). Normo-ovulatory infertile patients, with
      maternal age ≤35 years and at least two blastocysts with a morphology score of 2BB
      cryopreserved, will be randomized by computer-generated randomized allocation to either the
      PGT or morphology arm of the trial. All transfers will be single embryo transfers (SET), with
      only the first FET cycles following freeze-all to be analyzed.

      Consent and Ethics Akdeniz University Medical Faculty Clinical Research Ethics Committee has
      approved the trial (reference number: 2015/399), with anonymized results to be released in
      ClinicalTrials.gov. All patients will provide informed consent, which included an agreement
      for the use of anonymised data for research and SET.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction Embryo aneuploidy is likely the leading cause of implantation failure in IVF
      cycles. Since the inception of IVF, non-invasive morphology based scoring has been the most
      widely used embryo selection method, resulting in relatively low embryo implantation rates.
      Embryo morphology assessment methods have significant limitations (i.e., the assessments are
      subjective and the method uses fixed time-point assessments to define dynamic embryo
      development) and shortcomings (i.e., exposes embryos to sub-optimal conditions during
      assessment). Notwithstanding the limitations and shortcomings of this method its use
      worldwide has continued, because it is a relatively simple and non-invasive method and its
      scores have been shown to be (moderately) positively correlated to embryo euploidy, ongoing
      pregnancy, and live birth (Van Royen et al., 1999, Ahlstrom et al., 2011, Forman et al.,
      2013, Capalbo et al., 2014, Oron et al., 2014, Rhenman et al., 2015).

      However multiple gestations still represents one of the most significant complications in
      IVF, which are mainly the result of multiple-embryo embryo transfers, with multiple-embryo
      transfers used to overcome the relatively low embryo implantation rates in IVF. Our
      understanding of the optimal conditions required for in vitro embryo culture in IVF has
      advanced significantly in the past two decades. The implementation of improved in vitro
      embryo culture technologies (i.e., culture media and incubators) has resulted in an increase
      in the number of good quality embryos and consequently in the numbers of blastocysts. While
      blastocyst transfers have seemingly improved the reproductive outcomes in IVF, the use of SET
      and PGT technologies have revealed embryo implantation still to be sub-optimal (Schoolcraft
      et al., 2013). New CCS platforms are a major breakthrough in PGT, allowing 24-chromosome
      screening to be performed with high degree of accuracy from single cells (Harper and Harton,
      2010). The evidence that morphology scores were only moderately associated with euploidy and
      that the transfer of PGT predicted euploid embryos resulted in higher implantation rates
      (Dahdouh et al., 2015), has seen the continued use of morphology-based scoring methods
      increasingly being challenged.

      In addition to all the other advances in IVF, significant improvements have also been made in
      cryopreservation technologies. These improvements have resulted in significant improvements
      in frozen-thawed embryo survival (i.e. minimizing of risks), post-thaw developmental
      competence (Cobo et al., 2012; Balaban et al., 2008), and in the reproductive outcomes of FET
      (Evans et al., 2014; Ozgur et al., 2015). The benefits of FET include; the transfer of
      embryos to a more physiologic endometrium (i.e., early luteal phase), the ability to time
      transfers more accurately, and the ability to use patient-specific endometrial preparations
      (Casper and Yanushpolsky, 2016, Franasiak et al., 2016; Groenewoud et al., 2013, Yarali et
      al., 2016).

      Moreover, the hypotheses of PGT requires to be confirmed in further robust RCT before its
      implementation in routine IVF.

      Objectives The primary objective of this RCT will be to investigate whether PGT for
      aneuploidy as a blastocyst selection method is superior to standard morphology scoring
      blastocyst selection, comparing the reproductive outcomes in FET cycles. The decision to
      transfer all blastocysts in FET will eliminate any potential impact of ovarian stimulation
      confounding on endometrial receptivity and to use freeze-all cycles will allow the use of the
      primary blastocysts of blastocyst cohorts. The primary outcome measure of this trial will be
      LB, with a LB defined as a pregnancy cycle delivering at &gt;20 weeks of gestation.

      Secondary objectives The secondary objective of the RCT will be to investigate whether
      euploid blastocyst transfer results in reduced miscarriage, with a miscarriage defined as a
      clinical pregnancy lost at &lt;20 weeks of gestation.

      Keywords: blastocyst; comprehensive chromosome screening; euploidy; frozen embryo transfer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Actual">February 21, 2018</completion_date>
  <primary_completion_date type="Actual">February 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single-centre randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients With a Live Birth</measure>
    <time_frame>&gt;20 weeks gestation</time_frame>
    <description>A live birth cycle was defined as a cycle with a delivery after 20 weeks of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients With a Clinical Pregnancy</measure>
    <time_frame>&gt;5 weeks of gestation</time_frame>
    <description>A clinical pregnancy was defined as a cycle with a fetal sac observed on ultrasound after 5 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Pregnancies That Miscarried</measure>
    <time_frame>&lt;20 weeks</time_frame>
    <description>A miscarriage was defined as the loss of a clinical pregnancy before 20 weeks of gestation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>PGT-A group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Next Generation sequencing preimplantation genetic testing for aneuploidy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphology group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>morphological assessment of blastocyst by light microscope</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>comprehensive chromosome screening</intervention_name>
    <description>Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).</description>
    <arm_group_label>PGT-A group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient-couples eligible for inclusion in the trial must satisfy the following criteria;
        female age of ≤35 years, female body mass index (BMI) of ≥18 or ≤35 kg/m2, antral follicle
        count (AFC) of ≥10, normo-ovulatory, intend to use autologous oocytes, and have ≥2
        blastocysts with a morphological score of 2BB on day 5 of embryo development

        Exclusion Criteria:

        Patient couples will be excluded from the trial for the following reasons, patients with
        drug contraindications, patients with pathophysiology unrelated to reproduction, patients
        with intrauterine pathophysiologies, patients with no blastocysts, patients with &lt;2
        blastocysts with a morphological score of 2BB.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Coetzee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya IVF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antalya IVF</name>
      <address>
        <city>Antalya</city>
        <zip>07080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Ahlström A, Westin C, Reismer E, Wikland M, Hardarson T. Trophectoderm morphology: an important parameter for predicting live birth after single blastocyst transfer. Hum Reprod. 2011 Dec;26(12):3289-96. doi: 10.1093/humrep/der325. Epub 2011 Oct 3.</citation>
    <PMID>21972253</PMID>
  </results_reference>
  <results_reference>
    <citation>Balaban B, Urman B, Ata B, Isiklar A, Larman MG, Hamilton R, Gardner DK. A randomized controlled study of human Day 3 embryo cryopreservation by slow freezing or vitrification: vitrification is associated with higher survival, metabolism and blastocyst formation. Hum Reprod. 2008 Sep;23(9):1976-82. doi: 10.1093/humrep/den222. Epub 2008 Jun 10.</citation>
    <PMID>18544577</PMID>
  </results_reference>
  <results_reference>
    <citation>Capalbo A, Rienzi L, Cimadomo D, Maggiulli R, Elliott T, Wright G, Nagy ZP, Ubaldi FM. Correlation between standard blastocyst morphology, euploidy and implantation: an observational study in two centers involving 956 screened blastocysts. Hum Reprod. 2014 Jun;29(6):1173-81. doi: 10.1093/humrep/deu033. Epub 2014 Feb 26.</citation>
    <PMID>24578475</PMID>
  </results_reference>
  <results_reference>
    <citation>Casper RF, Yanushpolsky EH. Optimal endometrial preparation for frozen embryo transfer cycles: window of implantation and progesterone support. Fertil Steril. 2016 Apr;105(4):867-72. doi: 10.1016/j.fertnstert.2016.01.006. Epub 2016 Jan 25. Review.</citation>
    <PMID>26820769</PMID>
  </results_reference>
  <results_reference>
    <citation>Cobo A, de los Santos MJ, Castellò D, Gámiz P, Campos P, Remohí J. Outcomes of vitrified early cleavage-stage and blastocyst-stage embryos in a cryopreservation program: evaluation of 3,150 warming cycles. Fertil Steril. 2012 Nov;98(5):1138-46.e1. doi: 10.1016/j.fertnstert.2012.07.1107. Epub 2012 Aug 3.</citation>
    <PMID>22862909</PMID>
  </results_reference>
  <results_reference>
    <citation>Dahdouh EM, Balayla J, García-Velasco JA. Comprehensive chromosome screening improves embryo selection: a meta-analysis. Fertil Steril. 2015 Dec;104(6):1503-12. doi: 10.1016/j.fertnstert.2015.08.038. Epub 2015 Sep 16. Review.</citation>
    <PMID>26385405</PMID>
  </results_reference>
  <results_reference>
    <citation>Evans J, Hannan NJ, Edgell TA, Vollenhoven BJ, Lutjen PJ, Osianlis T, Salamonsen LA, Rombauts LJ. Fresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence. Hum Reprod Update. 2014 Nov-Dec;20(6):808-21. doi: 10.1093/humupd/dmu027. Epub 2014 Jun 10. Review.</citation>
    <PMID>24916455</PMID>
  </results_reference>
  <results_reference>
    <citation>Forman EJ, Upham KM, Cheng M, Zhao T, Hong KH, Treff NR, Scott RT Jr. Comprehensive chromosome screening alters traditional morphology-based embryo selection: a prospective study of 100 consecutive cycles of planned fresh euploid blastocyst transfer. Fertil Steril. 2013 Sep;100(3):718-24. doi: 10.1016/j.fertnstert.2013.04.043. Epub 2013 May 30.</citation>
    <PMID>23725804</PMID>
  </results_reference>
  <results_reference>
    <citation>Franasiak JM, Ruiz-Alonso M, Scott RT, Simón C. Both slowly developing embryos and a variable pace of luteal endometrial progression may conspire to prevent normal birth in spite of a capable embryo. Fertil Steril. 2016 Apr;105(4):861-6. doi: 10.1016/j.fertnstert.2016.02.030. Review.</citation>
    <PMID>26940791</PMID>
  </results_reference>
  <results_reference>
    <citation>Groenewoud ER, Cantineau AE, Kollen BJ, Macklon NS, Cohlen BJ. What is the optimal means of preparing the endometrium in frozen-thawed embryo transfer cycles? A systematic review and meta-analysis. Hum Reprod Update. 2013 Sep-Oct;19(5):458-70. doi: 10.1093/humupd/dmt030. Epub 2013 Jul 2. Review. Erratum in: Hum Reprod Update. 2017 Mar 1;23(2):255-261.</citation>
    <PMID>23820515</PMID>
  </results_reference>
  <results_reference>
    <citation>Harper JC, Harton G. The use of arrays in preimplantation genetic diagnosis and screening. Fertil Steril. 2010 Sep;94(4):1173-7. doi: 10.1016/j.fertnstert.2010.04.064. Epub 2010 Jun 25. Review.</citation>
    <PMID>20579641</PMID>
  </results_reference>
  <results_reference>
    <citation>Oron G, Son WY, Buckett W, Tulandi T, Holzer H. The association between embryo quality and perinatal outcome of singletons born after single embryo transfers: a pilot study. Hum Reprod. 2014 Jul;29(7):1444-51. Epub 2014 May 8.</citation>
    <PMID>24812313</PMID>
  </results_reference>
  <results_reference>
    <citation>Özgür K, Berkkanoğlu M, Bulut H, Isikli A, Coetzee K. Higher clinical pregnancy rates from frozen-thawed blastocyst transfers compared to fresh blastocyst transfers: a retrospective matched-cohort study. J Assist Reprod Genet. 2015 Oct;32(10):1483-90. doi: 10.1007/s10815-015-0576-1. Epub 2015 Sep 23.</citation>
    <PMID>26400506</PMID>
  </results_reference>
  <results_reference>
    <citation>Rhenman A, Berglund L, Brodin T, Olovsson M, Milton K, Hadziosmanovic N, Holte J. Which set of embryo variables is most predictive for live birth? A prospective study in 6252 single embryo transfers to construct an embryo score for the ranking and selection of embryos. Hum Reprod. 2015 Jan;30(1):28-36. doi: 10.1093/humrep/deu295. Epub 2014 Nov 5.</citation>
    <PMID>25376459</PMID>
  </results_reference>
  <results_reference>
    <citation>Schoolcraft WB, Katz-Jaffe MG. Comprehensive chromosome screening of trophectoderm with vitrification facilitates elective single-embryo transfer for infertile women with advanced maternal age. Fertil Steril. 2013 Sep;100(3):615-9. doi: 10.1016/j.fertnstert.2013.07.1972. Review.</citation>
    <PMID>23993664</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Royen E, Mangelschots K, De Neubourg D, Valkenburg M, Van de Meerssche M, Ryckaert G, Eestermans W, Gerris J. Characterization of a top quality embryo, a step towards single-embryo transfer. Hum Reprod. 1999 Sep;14(9):2345-9.</citation>
    <PMID>10469708</PMID>
  </results_reference>
  <results_reference>
    <citation>Yarali H, Polat M, Mumusoglu S, Yarali I, Bozdag G. Preparation of endometrium for frozen embryo replacement cycles: a systematic review and meta-analysis. J Assist Reprod Genet. 2016 Oct;33(10):1287-1304. Epub 2016 Aug 22. Review.</citation>
    <PMID>27549760</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <results_first_submitted>April 25, 2018</results_first_submitted>
  <results_first_submitted_qc>March 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2019</results_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Antalya IVF</investigator_affiliation>
    <investigator_full_name>Kevin Coetzee</investigator_full_name>
    <investigator_title>Scientific advisor</investigator_title>
  </responsible_party>
  <keyword>morphological score</keyword>
  <keyword>preimplantation genetic testing</keyword>
  <keyword>frozen embryo transfer</keyword>
  <keyword>blastocyst</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03095053/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patient population of the RCT consisted of patients who underwent autologous blastocyst freeze-all IVF cycles between March and October 2016, at a private IVF center</recruitment_details>
      <pre_assignment_details>Excluded (N =82) Patients with no blastocyst Patients with &lt;2 blastocysts Patients with only one 2BB blastocyst</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PGT-A Group</title>
          <description>comprehensive chromosome screening
comprehensive chromosome screening: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).</description>
        </group>
        <group group_id="P2">
          <title>Morphology Group</title>
          <description>morphological assessment of blastocyst by light microscope</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109">All blastocysts scored morphologically PGT-A of the single best blastocyst from the cohort</participants>
                <participants group_id="P2" count="111">All blastocysts scored morphologically</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80">29 excluded as blastocyst was predicted to be aneuploid</participants>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PGT-A Group</title>
          <description>comprehensive chromosome screening
comprehensive chromosome screening: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).</description>
        </group>
        <group group_id="B2">
          <title>Morphology Group</title>
          <description>morphological assessment of blastocyst by light microscope</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Female patients aged &gt;18 and ≤35 years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="3.71"/>
                    <measurement group_id="B2" value="28.3" spread="3.24"/>
                    <measurement group_id="B3" value="28.4" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>Infertile couples included based on female factors</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <description>Body mass index (BMI) is quantitative classification of weight using the measures of height and weight</description>
          <units>kg/m^2&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="4.11"/>
                    <measurement group_id="B2" value="25.1" spread="4.49"/>
                    <measurement group_id="B3" value="25.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antral follicle count</title>
          <description>transvaginal ultrasound examination</description>
          <units>number of antral follicles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.9" spread="14.16"/>
                    <measurement group_id="B2" value="24.2" spread="16.28"/>
                    <measurement group_id="B3" value="23.1" spread="15.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infertility duration</title>
          <description>years of unprotected sex without successful pregnancy</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="2.64"/>
                    <measurement group_id="B2" value="4.4" spread="3.10"/>
                    <measurement group_id="B3" value="4.2" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients With a Live Birth</title>
        <description>A live birth cycle was defined as a cycle with a delivery after 20 weeks of gestation.</description>
        <time_frame>&gt;20 weeks gestation</time_frame>
        <population>The live birth rates in the study trial groups</population>
        <group_list>
          <group group_id="O1">
            <title>Euploid Subgroup</title>
            <description>comprehensive chromosome screening
comprehensive chromosome screening: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).</description>
          </group>
          <group group_id="O2">
            <title>Morphology Group</title>
            <description>morphological assessment of blastocyst by light microscope</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With a Live Birth</title>
          <description>A live birth cycle was defined as a cycle with a delivery after 20 weeks of gestation.</description>
          <population>The live birth rates in the study trial groups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients With a Clinical Pregnancy</title>
        <description>A clinical pregnancy was defined as a cycle with a fetal sac observed on ultrasound after 5 weeks of gestation</description>
        <time_frame>&gt;5 weeks of gestation</time_frame>
        <population>The clinical pregnancy rates in the study trial groups</population>
        <group_list>
          <group group_id="O1">
            <title>Euploid Subgroup</title>
            <description>comprehensive chromosome screening
comprehensive chromosome screening: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).</description>
          </group>
          <group group_id="O2">
            <title>Morphology Group</title>
            <description>morphological assessment of blastocyst by light microscope</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With a Clinical Pregnancy</title>
          <description>A clinical pregnancy was defined as a cycle with a fetal sac observed on ultrasound after 5 weeks of gestation</description>
          <population>The clinical pregnancy rates in the study trial groups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Pregnancies That Miscarried</title>
        <description>A miscarriage was defined as the loss of a clinical pregnancy before 20 weeks of gestation.</description>
        <time_frame>&lt;20 weeks</time_frame>
        <population>The miscarriage rates in the study trial groups</population>
        <group_list>
          <group group_id="O1">
            <title>Euploid Subgroup</title>
            <description>comprehensive chromosome screening
comprehensive chromosome screening: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).</description>
          </group>
          <group group_id="O2">
            <title>Morphology Group</title>
            <description>morphological assessment of blastocyst by light microscope</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Pregnancies That Miscarried</title>
          <description>A miscarriage was defined as the loss of a clinical pregnancy before 20 weeks of gestation.</description>
          <population>The miscarriage rates in the study trial groups</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed-up for adverse events from the start date of ovarian stimulation to the final outcome of segmented IVF treatment; approximately 37 weeks for not pregnant patients and 77 weeks for pregnant patients</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PGT-A Group</title>
          <description>comprehensive chromosome screening
comprehensive chromosome screening: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).</description>
        </group>
        <group group_id="E2">
          <title>Morphology Group</title>
          <description>morphological assessment of blastocyst by light microscope</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Coetzee</name_or_title>
      <organization>Antalya IVF</organization>
      <phone>090 530 764 3135</phone>
      <email>kevincoetzee61@yahoo.co.nz</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

